GOODMAN AND GILMAN'S THE
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
Q1
Reference
Ch. 1 — Natural Products as Leads: Translational Considerations
Stem
A 68-year-old patient with chronic heart failure is taking
multiple drugs and you’re on a translational team screening
natural products for novel positive inotropes. An extract from a
medicinal plant shows in vitro enhancement of cardiomyocyte
contractility but also strong inhibition of human hepatic CYP3A4
,in hepatocyte assays. As lead optimization begins, which
problem should most directly influence immediate lead-
selection decisions?
A. The extract’s in vitro contractility effect suggests efficacy, so
prioritize potency optimization.
B. Strong CYP3A4 inhibition suggests high risk for drug–drug
interactions; deprioritize without further profiling.
C. Natural origin implies acceptable safety; move forward to in
vivo efficacy models.
D. Hepatic metabolic liability can be ignored early; focus on oral
bioavailability first.
Correct answer
B
Rationale — Correct (B)
Strong CYP3A4 inhibition predicts clinically significant drug–
drug interactions, especially in elderly, polypharmacy patients.
Early detection of metabolic liabilities is crucial in lead selection
because overcoming a potent CYP inhibitor pharmacophore is
often difficult and may require de-prioritization or structural
redesign. Addressing DDI risk early preserves translational
viability and patient safety.
Rationale — Incorrect
A. Potency alone ignores safety and interaction risks; optimizing
potency without fixing metabolic inhibition risks clinical failure.
C. Natural origin does not guarantee safety; many natural
compounds have toxic or interaction liabilities.
,D. Metabolic liabilities should not be ignored early—doing so
can waste resources on leads unlikely to be safe in humans.
Teaching Point
Early DDI (CYP) liabilities often determine whether a natural
lead is translatable.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q2
Reference
Ch. 1 — Target Identification & Validation: Genetic and
Phenotypic Approaches
Stem
Your team is deciding between a target-based strategy (well-
validated enzyme) and a phenotypic screen for a
neurodegenerative disease with uncertain pathophysiology. A
patient-derived induced pluripotent stem cell (iPSC) model
shows complex disease phenotypes but lower throughput.
Which justification best supports choosing a phenotypic screen
in early discovery?
A. Phenotypic screens require no knowledge of mechanism;
they guarantee easier regulatory approval.
B. When pathophysiology is poorly understood, phenotypic
screens increase chances of discovering compounds that
,correct integrated cellular dysfunction.
C. Target-based approaches always outperform phenotypic
screens for complex diseases.
D. Phenotypic screening eliminates the need for subsequent
mechanistic studies.
Correct answer
B
Rationale — Correct (B)
Phenotypic screens test compounds against integrated disease
phenotypes and can identify agents that modulate complex,
multi-pathway dysfunction—valuable when specific molecular
drivers are unclear. Though lower throughput, they may yield
translationally relevant hits that target emergent properties not
captured by single-target assays.
Rationale — Incorrect
A. Lack of mechanism knowledge doesn’t equate to simpler
approval; regulators require safety and mechanism exploration
later.
C. Target-based approaches are powerful when targets are
validated, but not universally superior for multifactorial
diseases.
D. Phenotypic hits still require mechanistic deconvolution for
optimization and safety assessment.
Teaching Point
Phenotypic screens can discover drugs that act on integrated
disease biology when targets are uncertain.
,Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q3
Reference
Ch. 1 — High-Throughput Screening (HTS) vs. Virtual Screening
Stem
A biotech startup must choose between physical HTS of 500,000
compounds and an in-silico virtual screen of a 10-million
compound library against an X-ray structure of the target. The
target has a well-defined active site but is conformationally
flexible. Which strategy best balances speed, cost, and hit
quality?
A. Choose HTS because physical assays capture flexibility and
allosteric effects better.
B. Choose virtual screening only; it's cheaper and always
identifies better leads.
C. Combine virtual screening to narrow candidates, then HTS on
the top subset to confirm activity and capture conformational
dynamics.
D. Select neither; fragment-based design is the only valid
approach for flexible targets.
Correct answer
C
,Rationale — Correct (C)
A tiered strategy uses virtual screening to rapidly and cost-
effectively prioritize millions of compounds, then confirms hits
with HTS or biophysical assays that better capture
conformational flexibility and allosteric binding. This hybrid
approach balances throughput, cost, and hit validation.
Rationale — Incorrect
A. HTS alone is costly and slower for very large libraries; it may
miss virtual-prioritized chemotypes.
B. Virtual screening is cost-effective but has limitations with
flexible targets; it benefits from experimental confirmation.
D. Fragment-based design is useful but not the sole valid
approach—combining methods is often optimal.
Teaching Point
Combine virtual screening and experimental validation for
flexible targets to improve hit quality cost-effectively.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q4
Reference
Ch. 1 — Structure-Based Drug Design & Molecular Dynamics
Stem
A candidate small molecule shows promising docking to an
,enzyme’s active site but rapidly loses predicted contacts during
molecular dynamics (MD) simulation due to loop movement.
What does the MD result most strongly suggest about the lead
optimization path?
A. Docking alone is definitive; proceed to animal testing.
B. The binding pose is unstable; optimize for interactions that
are preserved across physiologic conformations or shift to
scaffolds accommodating mobility.
C. MD instability is irrelevant if in vitro potency is high.
D. Discard the target; flexible enzymes cannot be drugged.
Correct answer
B
Rationale — Correct (B)
MD reveals conformational dynamics affecting ligand stability;
an unstable pose suggests the lead may not maintain binding in
physiological conditions. Optimization should focus on
conserved interactions across conformations or on scaffolds
that tolerate loop mobility to improve translational likelihood.
Rationale — Incorrect
A. Docking lacks dynamic context; relying solely on docking risks
false positives.
C. In vitro potency might reflect assay artifacts; unstable binding
raises translational risk despite potency.
D. Flexible enzymes can be targeted, but design must consider
dynamics rather than abandoning the target outright.
,Teaching Point
Molecular dynamics identifies conformational liabilities;
optimize for interactions stable across physiological motions.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q5
Reference
Ch. 1 — Fragment-Based Lead Discovery (FBLD)
Stem
In FBLD, low-molecular-weight fragments bind weakly but
efficiently. A fragment identified by NMR binds an allosteric
pocket and improves enzyme kinetics modestly. Which strategy
best advances this fragment toward a potent drug candidate?
A. Increase molecular weight by adding polar groups to raise
ligand efficiency.
B. Link or grow the fragment to engage adjacent binding
subsites while monitoring ligand efficiency and ADMET.
C. Discard fragment hits—weak binding indicates poor
potential.
D. Immediately synthesize large combinatorial libraries around
the fragment without structure guidance.
Correct answer
B
,Rationale — Correct (B)
Fragment growth/linking to engage adjacent subsites is the
canonical FBLD path—carefully increasing interactions while
preserving ligand efficiency and monitoring ADMET properties.
Structure-guided elaboration maximizes potency gains from
efficient fragments.
Rationale — Incorrect
A. Arbitrary addition of polar groups can reduce membrane
permeability and increase clearance; additions must be guided
by structure and efficiency metrics.
C. Weak binding is expected for fragments; they are valuable
starting points when efficiently elaborated.
D. Unguided combinatorial expansion risks wasted effort and
poor physicochemical properties; structure guidance is critical.
Teaching Point
Fragment hits are optimized by structure-guided
growth/linking, balancing potency and ADMET.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q6
Reference
Ch. 1 — QSAR and Ligand-Based Design
, Stem
A medicinal chemist uses QSAR models built on a series of
analogues to predict activity for new compounds. A patient
population of interest has high prevalence of renal impairment.
How should ADMET considerations alter QSAR-driven candidate
selection?
A. QSAR models predict only potency; ADMET is irrelevant to
selection.
B. Integrate ADMET descriptors (e.g., predicted renal clearance,
plasma protein binding) into the QSAR or apply parallel ADMET
filters to prioritize molecules with favorable renal handling.
C. Favor highly renally cleared compounds to avoid hepatic
metabolism complexity.
D. Reject QSAR entirely for renal patient populations.
Correct answer
B
Rationale — Correct (B)
QSAR can be extended to include ADMET descriptors or used
alongside predictive ADMET filters to select molecules with
acceptable renal clearance and toxicity profiles—critical for
populations with renal impairment. Early integration reduces
later attrition risks.
Rationale — Incorrect
A. Ignoring ADMET leads to candidates with unacceptable PK or
toxicity in target populations.
C. Favoring high renal clearance could be harmful in renal
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
Q1
Reference
Ch. 1 — Natural Products as Leads: Translational Considerations
Stem
A 68-year-old patient with chronic heart failure is taking
multiple drugs and you’re on a translational team screening
natural products for novel positive inotropes. An extract from a
medicinal plant shows in vitro enhancement of cardiomyocyte
contractility but also strong inhibition of human hepatic CYP3A4
,in hepatocyte assays. As lead optimization begins, which
problem should most directly influence immediate lead-
selection decisions?
A. The extract’s in vitro contractility effect suggests efficacy, so
prioritize potency optimization.
B. Strong CYP3A4 inhibition suggests high risk for drug–drug
interactions; deprioritize without further profiling.
C. Natural origin implies acceptable safety; move forward to in
vivo efficacy models.
D. Hepatic metabolic liability can be ignored early; focus on oral
bioavailability first.
Correct answer
B
Rationale — Correct (B)
Strong CYP3A4 inhibition predicts clinically significant drug–
drug interactions, especially in elderly, polypharmacy patients.
Early detection of metabolic liabilities is crucial in lead selection
because overcoming a potent CYP inhibitor pharmacophore is
often difficult and may require de-prioritization or structural
redesign. Addressing DDI risk early preserves translational
viability and patient safety.
Rationale — Incorrect
A. Potency alone ignores safety and interaction risks; optimizing
potency without fixing metabolic inhibition risks clinical failure.
C. Natural origin does not guarantee safety; many natural
compounds have toxic or interaction liabilities.
,D. Metabolic liabilities should not be ignored early—doing so
can waste resources on leads unlikely to be safe in humans.
Teaching Point
Early DDI (CYP) liabilities often determine whether a natural
lead is translatable.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q2
Reference
Ch. 1 — Target Identification & Validation: Genetic and
Phenotypic Approaches
Stem
Your team is deciding between a target-based strategy (well-
validated enzyme) and a phenotypic screen for a
neurodegenerative disease with uncertain pathophysiology. A
patient-derived induced pluripotent stem cell (iPSC) model
shows complex disease phenotypes but lower throughput.
Which justification best supports choosing a phenotypic screen
in early discovery?
A. Phenotypic screens require no knowledge of mechanism;
they guarantee easier regulatory approval.
B. When pathophysiology is poorly understood, phenotypic
screens increase chances of discovering compounds that
,correct integrated cellular dysfunction.
C. Target-based approaches always outperform phenotypic
screens for complex diseases.
D. Phenotypic screening eliminates the need for subsequent
mechanistic studies.
Correct answer
B
Rationale — Correct (B)
Phenotypic screens test compounds against integrated disease
phenotypes and can identify agents that modulate complex,
multi-pathway dysfunction—valuable when specific molecular
drivers are unclear. Though lower throughput, they may yield
translationally relevant hits that target emergent properties not
captured by single-target assays.
Rationale — Incorrect
A. Lack of mechanism knowledge doesn’t equate to simpler
approval; regulators require safety and mechanism exploration
later.
C. Target-based approaches are powerful when targets are
validated, but not universally superior for multifactorial
diseases.
D. Phenotypic hits still require mechanistic deconvolution for
optimization and safety assessment.
Teaching Point
Phenotypic screens can discover drugs that act on integrated
disease biology when targets are uncertain.
,Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q3
Reference
Ch. 1 — High-Throughput Screening (HTS) vs. Virtual Screening
Stem
A biotech startup must choose between physical HTS of 500,000
compounds and an in-silico virtual screen of a 10-million
compound library against an X-ray structure of the target. The
target has a well-defined active site but is conformationally
flexible. Which strategy best balances speed, cost, and hit
quality?
A. Choose HTS because physical assays capture flexibility and
allosteric effects better.
B. Choose virtual screening only; it's cheaper and always
identifies better leads.
C. Combine virtual screening to narrow candidates, then HTS on
the top subset to confirm activity and capture conformational
dynamics.
D. Select neither; fragment-based design is the only valid
approach for flexible targets.
Correct answer
C
,Rationale — Correct (C)
A tiered strategy uses virtual screening to rapidly and cost-
effectively prioritize millions of compounds, then confirms hits
with HTS or biophysical assays that better capture
conformational flexibility and allosteric binding. This hybrid
approach balances throughput, cost, and hit validation.
Rationale — Incorrect
A. HTS alone is costly and slower for very large libraries; it may
miss virtual-prioritized chemotypes.
B. Virtual screening is cost-effective but has limitations with
flexible targets; it benefits from experimental confirmation.
D. Fragment-based design is useful but not the sole valid
approach—combining methods is often optimal.
Teaching Point
Combine virtual screening and experimental validation for
flexible targets to improve hit quality cost-effectively.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q4
Reference
Ch. 1 — Structure-Based Drug Design & Molecular Dynamics
Stem
A candidate small molecule shows promising docking to an
,enzyme’s active site but rapidly loses predicted contacts during
molecular dynamics (MD) simulation due to loop movement.
What does the MD result most strongly suggest about the lead
optimization path?
A. Docking alone is definitive; proceed to animal testing.
B. The binding pose is unstable; optimize for interactions that
are preserved across physiologic conformations or shift to
scaffolds accommodating mobility.
C. MD instability is irrelevant if in vitro potency is high.
D. Discard the target; flexible enzymes cannot be drugged.
Correct answer
B
Rationale — Correct (B)
MD reveals conformational dynamics affecting ligand stability;
an unstable pose suggests the lead may not maintain binding in
physiological conditions. Optimization should focus on
conserved interactions across conformations or on scaffolds
that tolerate loop mobility to improve translational likelihood.
Rationale — Incorrect
A. Docking lacks dynamic context; relying solely on docking risks
false positives.
C. In vitro potency might reflect assay artifacts; unstable binding
raises translational risk despite potency.
D. Flexible enzymes can be targeted, but design must consider
dynamics rather than abandoning the target outright.
,Teaching Point
Molecular dynamics identifies conformational liabilities;
optimize for interactions stable across physiological motions.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q5
Reference
Ch. 1 — Fragment-Based Lead Discovery (FBLD)
Stem
In FBLD, low-molecular-weight fragments bind weakly but
efficiently. A fragment identified by NMR binds an allosteric
pocket and improves enzyme kinetics modestly. Which strategy
best advances this fragment toward a potent drug candidate?
A. Increase molecular weight by adding polar groups to raise
ligand efficiency.
B. Link or grow the fragment to engage adjacent binding
subsites while monitoring ligand efficiency and ADMET.
C. Discard fragment hits—weak binding indicates poor
potential.
D. Immediately synthesize large combinatorial libraries around
the fragment without structure guidance.
Correct answer
B
,Rationale — Correct (B)
Fragment growth/linking to engage adjacent subsites is the
canonical FBLD path—carefully increasing interactions while
preserving ligand efficiency and monitoring ADMET properties.
Structure-guided elaboration maximizes potency gains from
efficient fragments.
Rationale — Incorrect
A. Arbitrary addition of polar groups can reduce membrane
permeability and increase clearance; additions must be guided
by structure and efficiency metrics.
C. Weak binding is expected for fragments; they are valuable
starting points when efficiently elaborated.
D. Unguided combinatorial expansion risks wasted effort and
poor physicochemical properties; structure guidance is critical.
Teaching Point
Fragment hits are optimized by structure-guided
growth/linking, balancing potency and ADMET.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Q6
Reference
Ch. 1 — QSAR and Ligand-Based Design
, Stem
A medicinal chemist uses QSAR models built on a series of
analogues to predict activity for new compounds. A patient
population of interest has high prevalence of renal impairment.
How should ADMET considerations alter QSAR-driven candidate
selection?
A. QSAR models predict only potency; ADMET is irrelevant to
selection.
B. Integrate ADMET descriptors (e.g., predicted renal clearance,
plasma protein binding) into the QSAR or apply parallel ADMET
filters to prioritize molecules with favorable renal handling.
C. Favor highly renally cleared compounds to avoid hepatic
metabolism complexity.
D. Reject QSAR entirely for renal patient populations.
Correct answer
B
Rationale — Correct (B)
QSAR can be extended to include ADMET descriptors or used
alongside predictive ADMET filters to select molecules with
acceptable renal clearance and toxicity profiles—critical for
populations with renal impairment. Early integration reduces
later attrition risks.
Rationale — Incorrect
A. Ignoring ADMET leads to candidates with unacceptable PK or
toxicity in target populations.
C. Favoring high renal clearance could be harmful in renal
